Marijuana Inc (MAJI)

$0.11 +0.01 (10.22%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 51,300
Avg Vol 70,550
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 59%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Marijuana Inc. distributes cannabis products in the United States. The company was formerly known as GRN Holding Corporation and changed its name to Marijuana Inc. in October 2024. Marijuana Inc. was founded in 2010 and is based in Estero, Florida.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 239 273 3344
Address:
21301 S Tamiami Tri, Suite 320 PMB 177, Estero, United States
rambo222
rambo222 Oct. 22 at 3:06 PM
$MAJI Looks pretty dead to me. Another trash company doing nothing but saying a lot.
0 · Reply
Pennystockes
Pennystockes Oct. 4 at 6:40 AM
MAJI / Exousia AI – Real Assets Behind the Story For those wondering if $MAJI has anything real behind it, here are some key facts I’ve been able to verify: ✅ Acquisition of Exousia AI – On Jan 6, 2025 MAJI acquired 100% of Exousia AI, issuing 47M restricted shares to Ludwig Enterprises. ✅ Provisional Patent Filed – On Sept 10, 2025, Exousia Pro filed provisional patent #63/877,517 for a novel extracellular vesicle loading method to improve efficiency and stability of therapeutic delivery. ✅ Orphan Drug Application – FDA requested additional data regarding Exousia AI’s Orphan Drug designation filing for glioblastoma. Study underway at UCF, expected results by mid-year. ✅ Renegotiated License with Progenicyte – Agreement revised from 50% to 30% equity in exchange for worldwide rights to the exosome patent. ✅ Corporate Development – New divisions launched (Exousia Health, Exousia Wholesale, etc.) and FINRA filings in process for subsidiary name changes. ✅ Reg A Offering
0 · Reply
Thewho12
Thewho12 Oct. 1 at 5:45 PM
$MAJI this stock isnt moving
1 · Reply
Zardiw
Zardiw Sep. 30 at 10:54 PM
$MAJI - FDA Orphan Designation Benefits: 7-year market exclusivity - FDA can't approve competing drugs for the same indication during this period Tax credits - 25% credit on qualified clinical testing costs Fee waivers - FDA application fees waived (normally ~$3 million) Grant eligibility - Access to FDA orphan products grants for clinical trials Regulatory assistance - Direct FDA guidance and protocol assistance Z
0 · Reply
Zardiw
Zardiw Sep. 30 at 10:37 PM
$MAJI DD Post: MAJI / Exousia AI – Real Assets Behind the Story For those wondering if $MAJI has anything real behind it, here are some key facts I’ve been able to verify: ✅ Acquisition of Exousia AI – On Jan 6, 2025 MAJI acquired 100% of Exousia AI, issuing 47M restricted shares to Ludwig Enterprises. ✅ Provisional Patent Filed – On Sept 10, 2025, Exousia Pro filed provisional patent #63/877,517 for a novel extracellular vesicle loading method to improve efficiency and stability of therapeutic delivery. ✅ Orphan Drug Application – FDA requested additional data regarding Exousia AI’s Orphan Drug designation filing for glioblastoma. Study underway at UCF, expected results by mid-year. ✅ Renegotiated License with Progenicyte – Agreement revised from 50% to 30% equity in exchange for worldwide rights to the exosome patent. ✅ Corporate Development – New divisions launched (Exousia Health, Exousia Wholesale, etc.) and FINRA filings in process for subsidiary name changes.
0 · Reply
Thewho12
Thewho12 Sep. 30 at 9:17 PM
$MAJI omg orphan drug? this will be huge
0 · Reply
TheHyena
TheHyena Sep. 30 at 9:15 PM
$MAJI I’m assuming this has to do with their orphan drug designation.
0 · Reply
Zardiw
Zardiw Sep. 30 at 8:53 PM
$MAJI - FDA Grants Orphan Drug Designation! ....That's HUGE! Z
0 · Reply
Zardiw
Zardiw Sep. 30 at 6:05 PM
$MAJI
0 · Reply
Zardiw
Zardiw Sep. 30 at 6:04 PM
$MAJI Going................Z
0 · Reply
Latest News on MAJI
No data available.
rambo222
rambo222 Oct. 22 at 3:06 PM
$MAJI Looks pretty dead to me. Another trash company doing nothing but saying a lot.
0 · Reply
Pennystockes
Pennystockes Oct. 4 at 6:40 AM
MAJI / Exousia AI – Real Assets Behind the Story For those wondering if $MAJI has anything real behind it, here are some key facts I’ve been able to verify: ✅ Acquisition of Exousia AI – On Jan 6, 2025 MAJI acquired 100% of Exousia AI, issuing 47M restricted shares to Ludwig Enterprises. ✅ Provisional Patent Filed – On Sept 10, 2025, Exousia Pro filed provisional patent #63/877,517 for a novel extracellular vesicle loading method to improve efficiency and stability of therapeutic delivery. ✅ Orphan Drug Application – FDA requested additional data regarding Exousia AI’s Orphan Drug designation filing for glioblastoma. Study underway at UCF, expected results by mid-year. ✅ Renegotiated License with Progenicyte – Agreement revised from 50% to 30% equity in exchange for worldwide rights to the exosome patent. ✅ Corporate Development – New divisions launched (Exousia Health, Exousia Wholesale, etc.) and FINRA filings in process for subsidiary name changes. ✅ Reg A Offering
0 · Reply
Thewho12
Thewho12 Oct. 1 at 5:45 PM
$MAJI this stock isnt moving
1 · Reply
Zardiw
Zardiw Sep. 30 at 10:54 PM
$MAJI - FDA Orphan Designation Benefits: 7-year market exclusivity - FDA can't approve competing drugs for the same indication during this period Tax credits - 25% credit on qualified clinical testing costs Fee waivers - FDA application fees waived (normally ~$3 million) Grant eligibility - Access to FDA orphan products grants for clinical trials Regulatory assistance - Direct FDA guidance and protocol assistance Z
0 · Reply
Zardiw
Zardiw Sep. 30 at 10:37 PM
$MAJI DD Post: MAJI / Exousia AI – Real Assets Behind the Story For those wondering if $MAJI has anything real behind it, here are some key facts I’ve been able to verify: ✅ Acquisition of Exousia AI – On Jan 6, 2025 MAJI acquired 100% of Exousia AI, issuing 47M restricted shares to Ludwig Enterprises. ✅ Provisional Patent Filed – On Sept 10, 2025, Exousia Pro filed provisional patent #63/877,517 for a novel extracellular vesicle loading method to improve efficiency and stability of therapeutic delivery. ✅ Orphan Drug Application – FDA requested additional data regarding Exousia AI’s Orphan Drug designation filing for glioblastoma. Study underway at UCF, expected results by mid-year. ✅ Renegotiated License with Progenicyte – Agreement revised from 50% to 30% equity in exchange for worldwide rights to the exosome patent. ✅ Corporate Development – New divisions launched (Exousia Health, Exousia Wholesale, etc.) and FINRA filings in process for subsidiary name changes.
0 · Reply
Thewho12
Thewho12 Sep. 30 at 9:17 PM
$MAJI omg orphan drug? this will be huge
0 · Reply
TheHyena
TheHyena Sep. 30 at 9:15 PM
$MAJI I’m assuming this has to do with their orphan drug designation.
0 · Reply
Zardiw
Zardiw Sep. 30 at 8:53 PM
$MAJI - FDA Grants Orphan Drug Designation! ....That's HUGE! Z
0 · Reply
Zardiw
Zardiw Sep. 30 at 6:05 PM
$MAJI
0 · Reply
Zardiw
Zardiw Sep. 30 at 6:04 PM
$MAJI Going................Z
0 · Reply
fiddledjinn
fiddledjinn Sep. 30 at 6:02 PM
$MAJI https://x.com/NotTheMoma2/status/1973056832340983868?t=0I97gIPfhQvRsvjKZtGYqg&s=19
0 · Reply
TheHyena
TheHyena Sep. 30 at 5:52 PM
$MAJI Orphan Drug Designstion! This is huge.
0 · Reply
DiamondCapital
DiamondCapital Sep. 10 at 5:28 PM
$MAJI News out today! Filed a new Provisional Patent (no. 63/877,517) that embodies a groundbreaking method for loading Extracellular Vesicles (EVs) https://x.com/stockpicksnyc/status/1965819395466576133?s=46 News: https://www.accessnewswire.com/newsroom/en/exousia-pro-files-provisional-patent-for-novel-extracellular-vesicle-loading-method-tapping-into-m-1071199
1 · Reply
DiamondCapital
DiamondCapital Sep. 8 at 7:26 PM
$MAJI Nice set up here and barely anything on the ask https://x.com/stockpicksnyc/status/1965134133442814148?s=46
0 · Reply
DiamondCapital
DiamondCapital Sep. 8 at 5:29 PM
News article picked up by Benzinga!! Covering $BULT, $FRQN, $MAJI, $SPTY, $CFTN MicroCap Mag 7 Spotlight https://x.com/stockpicksnyc/status/1965104702183686618?s=46 Link to the article on Benzinga: https://www.benzinga.com/pressreleases/25/09/ab47528809/microcap-mag-7-spotlight-elmgf-maji-spty-sigl-more-inside
0 · Reply
DiamondCapital
DiamondCapital Sep. 8 at 3:22 PM
OTC Watchlist no darts all gem plays with forward looking catalysts Also on the list $FRQN $MAJI $TWOH $CBLO $DTII Full list here: https://x.com/stockpicksnyc/status/1965049339178619286?s=46
0 · Reply
DiamondCapital
DiamondCapital Sep. 5 at 5:01 PM
$LRGR, $MAJI, $TWOH, $CBLO $DTREF Some more plays that will be discussed during open mic after the PKLE Investor Q&A Hit the reminder button so you get a notification when we go live on “X” Twitter Here: https://x.com/stockpicksnyc/status/1964007740239487149?s=46
0 · Reply
DiamondCapital
DiamondCapital Sep. 5 at 4:51 PM
News article out now covering $BULT, $FRQN, $MAJI, $CFTN, $SPTY by ts_reports https://x.com/stockpicksnyc/status/1963995544432390165?s=46 MicroCap Mag 7 Spotlight Link to the article: https://thestreetreports.com/microcap-mag-7-spotlight-elmgf-maji-spty-sigl-more-inside
0 · Reply
DiamondCapital
DiamondCapital Sep. 3 at 3:49 PM
$MAJI News out! Exousia Pro Creates New Subdivisions and is expected to file 2 additional patents this month https://x.com/stockpicksnyc/status/1963248879551356974?s=46 Link to News: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/exousia-pro-creates-new-subdivisions-1068211
0 · Reply
SHEEPWOLF
SHEEPWOLF Sep. 3 at 2:05 PM
$MAJI : Exousia Pro Creates New Subdivisions The market for our new products is currently valued at $8.7 billion, projected to grow to $18.5 billion over the next decade. https://t.co/yIm1w8nuiK
0 · Reply
DiamondCapital
DiamondCapital Aug. 29 at 12:44 PM
Keep an eye on $MAJI 👀 Could see something from them real soon https://x.com/stockpicksnyc/status/1961403734413488407?s=46
0 · Reply
Muneer1978
Muneer1978 Aug. 27 at 5:14 PM
$LRGR $AIBT $BULT $AFFU $MAJI
1 · Reply